Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. Our lead asset, RPC1063, is being developed as an oral therapy for relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). Receptos is currently enrolling a Phase 3 study in RMS called RADIANCE, and has completed enrollment in a Phase 2 study in ulcerative colitis (a form of IBD) called TOUCHSTONE. Receptos is conducting a Phase 2 trial for RPC4046, a monoclonal antibody directed against interleukin-13 (IL-13), in patients with eosinophilic esophagitis (EoE).
Touchstone is no longer enrolling.
We are currently enrolling the Phase 2 study of RPC4046 in Eosinophilic Esophagitis (EoE). More information about HEROES enrolling locations and patient eligibility requirements can be found here.
We are currently enrolling the Phase 3 portion of an accelerated Phase 2/3 study of RPC1063 in RMS. More information about RADIANCE enrolling locations and patient eligibility requirements can be found here.
November 24, 2014
Receptos Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Completion of Underwritten Public Offering of Common Stock… MORE »
November 18, 2014
Receptos Announces Pricing of Underwritten Public Offering of Common Stock… MORE »
November 17, 2014
Receptos Announces Proposed Underwritten Public Offering of Common Stock… MORE »
November 6, 2014
Receptos to Present at Credit Suisse Healthcare Conference… MORE »